Satellos Bioscience Shares Climb After FDA Fast Track Designation

Dow Jones06-29 22:08

Satellos Bioscience's shares jumped Monday after the Duchenne treatment being developed by the biotechnology company received fast track designation in the U.S.

In morning trading, the shares rose 12% to C$11.39 in Toronto, widening the year-to-date advance to 44%.

Satellos said the Food and Drug Administration granted SAT-3247 fast track designation, a process designed to help development and expedite the review of drugs that treat serious conditions and address unmet medical needs.

The company is currently advancing SAT-3247 through ongoing Phase 2 studies in children and adults living with Duchenne muscular dystrophy.

Co-founder and Chief Executive Frank Gleeson said the recognition from the FDA, together with orphan drug and rare pediatric disease designations, further strengthens the momentum behind Satellos's clinical program.

Write to Robb M. Stewart at robb.stewart@wsj.com

(END) Dow Jones Newswires

June 29, 2026 10:08 ET (14:08 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2647377470?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 22:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647377470","market":"sg","top_or_hot":-1,"title":"Satellos Bioscience Shares Climb After FDA Fast Track Designation","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Satellos Bioscience's shares jumped Monday after the Duchenne treatment being developed by the biotechnology company received fast track designation in the U.S. \n</p>\n<p>\n  In morning trading, the shares rose 12% to C$11.39 in Toronto, widening the year-to-date advance to 44%. \n</p>\n<p>\n  Satellos said the Food and Drug Administration granted SAT-3247 fast track designation, a process designed to help development and expedite the review of drugs that treat serious conditions and address unmet medical needs. \n</p>\n<p>\n  The company is currently advancing SAT-3247 through ongoing Phase 2 studies in children and adults living with Duchenne muscular dystrophy. \n</p>\n<p>\n  Co-founder and Chief Executive Frank Gleeson said the recognition from the FDA, together with orphan drug and rare pediatric disease designations, further strengthens the momentum behind Satellos's clinical program. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 29, 2026 10:08 ET (14:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Satellos Bioscience Shares Climb After FDA Fast Track Designation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSatellos Bioscience Shares Climb After FDA Fast Track Designation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-29 22:08</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Satellos Bioscience's shares jumped Monday after the Duchenne treatment being developed by the biotechnology company received fast track designation in the U.S. \n</p>\n<p>\n  In morning trading, the shares rose 12% to C$11.39 in Toronto, widening the year-to-date advance to 44%. \n</p>\n<p>\n  Satellos said the Food and Drug Administration granted SAT-3247 fast track designation, a process designed to help development and expedite the review of drugs that treat serious conditions and address unmet medical needs. \n</p>\n<p>\n  The company is currently advancing SAT-3247 through ongoing Phase 2 studies in children and adults living with Duchenne muscular dystrophy. \n</p>\n<p>\n  Co-founder and Chief Executive Frank Gleeson said the recognition from the FDA, together with orphan drug and rare pediatric disease designations, further strengthens the momentum behind Satellos's clinical program. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 29, 2026 10:08 ET (14:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LABU","symbol_name":"三倍做多标普生物-Direxion","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2647377470","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647377470","pubTimestamp":1782742080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Satellos Bioscience's shares jumped Monday after the Duchenne treatment being developed by the biotechnology company received fast track designation in the U.S.In morning trading, the shares rose 12% to C$11.39 in Toronto, widening the year-to-date advance to 44%.Satellos said the Food and Drug Administration granted SAT-3247 fast track designation, a process designed to help development and expedite the review of drugs that treat serious conditions and address unmet medical needs.The company is currently advancing SAT-3247 through ongoing Phase 2 studies in children and adults living with Duchenne muscular dystrophy.Co-founder and Chief Executive Frank Gleeson said the recognition from the FDA, together with orphan drug and rare pediatric disease designations, further strengthens the momentum behind Satellos's clinical program.Write to Robb M. Stewart at robb.stewart@wsj.com Dow Jones NewswiresJune 29, 2026 10:08 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LABU":"三倍做多标普生物-Direxion","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"FDA快速通道指定后Satellos Bioscience股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5},"content_text":"Satellos Bioscience's shares jumped Monday after the Duchenne treatment being developed by the biotechnology company received fast track designation in the U.S. \n\n\n  In morning trading, the shares rose 12% to C$11.39 in Toronto, widening the year-to-date advance to 44%. \n\n\n  Satellos said the Food and Drug Administration granted SAT-3247 fast track designation, a process designed to help development and expedite the review of drugs that treat serious conditions and address unmet medical needs. \n\n\n  The company is currently advancing SAT-3247 through ongoing Phase 2 studies in children and adults living with Duchenne muscular dystrophy. \n\n\n  Co-founder and Chief Executive Frank Gleeson said the recognition from the FDA, together with orphan drug and rare pediatric disease designations, further strengthens the momentum behind Satellos's clinical program. \n\n\n \n\n\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 29, 2026 10:08 ET (14:08 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2647377470","isCrawlerRequest":true}